Neurocrine Biosciences ($NBIX) Insider Trading & Smart Money Activity
Neurocrine Biosciences, Inc. ($NBIX) has 8 insider trades, 2 13F position changes and 2 analyst ratings on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($3.34M), net -$3.34M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$3.34M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 2
NBIX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 2 · $3.34M | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 1 / 1 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All NBIX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Needham | Reiterates to Buy | PT $204 | Read | |||||||
| 13F | Ninety One UK | Added | +434.61K sh | $61.68M | Read | ||||||
| 13F | Moody Lynn Lieberson & Walker | Sold out | -12.59K sh | Read | |||||||
| Analyst | UBS | Reiterates to Buy | PT $214 | +5.2% | — | ||||||
| Insider | Darin LippoldtChief Legal Officer | Sell (Open-market sale) 10b5-1 | 9.80K sh | $1.67M | +2.4% | +6.3% | Read | ||||
| Insider | Darin LippoldtChief Legal Officer | Sell (Open-market sale) 10b5-1 | 9.80K sh | $1.67M | +2.4% | +6.3% | — | ||||
| Insider | Darin LippoldtChief Legal Officer | Buy (Option exercise) | 9.80K sh | $798.60K | +2.4% | +6.3% | Read | ||||
| Insider | Darin LippoldtChief Legal Officer | Buy (Option exercise) | 9.80K sh | $798.60K | +2.4% | +6.3% | Read | ||||
| Insider | Darin LippoldtChief Legal Officer | Sell (Option exercise) | 200 sh | +3.3% | +4.7% | — | |||||
| Insider | Darin LippoldtChief Legal Officer | Sell (Option exercise) | 200 sh | +3.3% | +4.7% | — | |||||
| Insider | Darin LippoldtChief Legal Officer | Buy (Option exercise) | 200 sh | $16.30K | +3.3% | +4.7% | Read | ||||
| Insider | Darin LippoldtChief Legal Officer | Buy (Option exercise) | 200 sh | $16.30K | +3.3% | +4.7% | Read |
1W / 1M / 6M = how NBIX moved from the trade or filing date.
Insider trading in NBIX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Darin Lippoldt | Chief Legal Officer | 8 | -$3.34M | Jun 29, 2026 |
Institutions moving NBIX (13F)
Analyst ratings on NBIX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Needham | Reiterates | Buy | $204 | Read | ||||
| UBS | Reiterates | Buy | $231 → $214 | +5.2% | — |
Frequently asked questions
Are NBIX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 2 open-market sales worth $3.34M, a net -$3.34M.
What is the latest insider trade in NBIX?
Darin Lippoldt, Chief Legal Officer filed a sell (open-market sale) of 9.80K sh worth $1.67M on Jun 29, 2026.
Which institutions changed their NBIX positions?
Recent 13F filers moving the stock include Ninety One UK and Moody Lynn Lieberson & Walker.
Other drug manufacturers - specialty & generic stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.